Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 13 of 151

  1. ARB-001467

    Arbutus Biopharma Corp

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial

  2. ARC-21(EDGE-Gastric)

    Arcus Biosciences

    Upper Gastrointestinal Tract Cancer, Advanced Upper Gastrointestinal Tract Malignancies, Gastrointestinal Tract Malignancies

    phase 2 small molecule active

    1 trial

  3. ARC-520

    Arrowhead Pharmaceuticals Ireland Limited

    Chronic Hepatitis B

    phase 2 small molecule terminated

    1 trial

  4. ARC-520

    Arrowhead Pharmaceuticals Ireland Limited

    Hepatitis B

    phase 2 small molecule terminated

    2 trials

  5. ARC-520

    Arrowhead Pharmaceuticals Ireland Limited

    Hepatitis B, Chronic

    phase 2 small molecule terminated

    1 trial

  6. ARC-520 Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Chronic Hepatitis B

    phase 2 small molecule terminated

    1 trial

  7. ARC-520 Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Hepatitis B

    phase 2 small molecule terminated

    2 trials

  8. ARC-9

    Arcus Biosciences

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  9. ARC-AAT Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Alpha-1 Antitrypsin Deficiency

    phase 2 small molecule terminated

    2 trials

  10. ARCT-021

    Arcturus Therapeutics Holdings

    SARS-CoV-2

    phase 2 mab terminated

    1 trial

  11. ARCT-021 Dose 1

    Arcturus Therapeutics Holdings

    SARS-CoV-2

    phase 2 mab completed

    1 trial

  12. ARCT-021 single dose priming

    Arcturus Therapeutics Holdings

    Covid19

    phase 2 mab terminated

    1 trial

  13. ARCT-032

    Arcturus Therapeutics Holdings

    Cystic Fibrosis

    phase 2 small molecule active

    2 trials

  14. ARCT-032-02

    Arcturus Therapeutics Holdings

    Cystic Fibrosis

    phase 2 other active

    1 trial

  15. ARCT-165

    Arcturus Therapeutics Holdings

    COVID-19

    phase 2 mab completed

    1 trial

  16. ARCT-810

    Arcturus Therapeutics Holdings

    Ornithine Transcarbamylase Deficiency

    phase 2 mab completed

    3 trials

  17. ARCT-810

    Arcturus Therapeutics Holdings

    OTC Deficiency

    phase 2 mab active

    1 trial

  18. ARD-101

    Ark Therapeutics

    Obesity

    phase 2 small molecule completed

    1 trial

  19. ARD-101

    Ark Therapeutics

    Bariatric Surgery

    phase 2 small molecule completed

    1 trial

  20. ARD-101

    Ark Therapeutics

    Prader-Willi Syndrome

    phase 2 small molecule completed

    1 trial

  21. ARD6122

    Regeneron UK Limited

    Neoplasms

    phase 2 small molecule completed

    1 trial

  22. ARD6123

    Regeneron UK Limited

    Pulmonary Diseases

    phase 2 small molecule completed

    1 trial

  23. ARGX-113-2302

    argenx

    Antibody-Mediated Rejection

    phase 2 small molecule active

    1 trial

  24. ARGX-113-2317

    argenx

    Systemic Sclerosis

    phase 2 small molecule active

    1 trial

  25. ARGX-117, ARGX-113

    argenx

    AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG

    phase 2 small molecule active

    1 trial

  26. ARGX-117-2003

    argenx

    Multifocal Motor Neuropathy

    phase 2 small molecule active

    1 trial

  27. ARGX-117-2301

    argenx

    Myositis, Dermatomyositis

    phase 2 small molecule active

    1 trial

  28. ARGX-119-2302

    argenx

    congenital neuromuscular disorders

    phase 2 other active

    1 trial

  29. ARGX-119-2303

    argenx

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  30. ARI-HER2

    The George Institute

    Patients with HER2Positive Advanced Breast Cancer

    phase 2 other active

    1 trial

  31. ARICEPT 10mg comprimidos recubiertos con película

    The George Institute

    Parkinson's disease

    phase 2 small molecule active

    1 trial

  32. ARK-E021 5%

    VYNE Therapeutics

    Acne Vulgaris

    phase 2 small molecule completed

    1 trial

  33. ARO-AAT

    Arrowhead Pharmaceuticals Ireland Limited

    Alpha 1-Antitrypsin Deficiency

    phase 2 small molecule completed

    1 trial

  34. ARO-ALK7

    Arrowhead Pharmaceuticals Ireland Limited

    Obesity

    phase 2 small molecule active

    1 trial

  35. ARO-ANG 3 Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Homozygous Familial Hypercholesterolemia

    phase 2 small molecule terminated

    1 trial

  36. ARO-ANG3

    Arrowhead Pharmaceuticals Ireland Limited

    Mixed Dyslipidemia

    phase 2 small molecule completed

    1 trial

  37. ARO-APOC3

    Arrowhead Pharmaceuticals Ireland Limited

    Mixed Dyslipidemia

    phase 2 small molecule active

    1 trial

  38. ARO-APOC3

    Arrowhead Pharmaceuticals Ireland Limited

    Mixed Dyslipidemia

    phase 2 small molecule completed

    1 trial

  39. ARO-APOC3

    Arrowhead Pharmaceuticals Ireland Limited

    Severe Hypertriglyceridemia

    phase 2 small molecule completed

    1 trial

  40. ARO-APOC3

    Arrowhead Pharmaceuticals Ireland Limited

    Dyslipidemias

    phase 2 small molecule completed

    1 trial

  41. ARO-C3

    Arrowhead Pharmaceuticals Ireland Limited

    complement-mediated renal disease

    phase 2 small molecule active

    1 trial

  42. ARO-C3

    Arrowhead Pharmaceuticals Ireland Limited

    C3 Glomerulopathy

    phase 2 small molecule completed

    1 trial

  43. ARO-DIMERPA

    Arrowhead Pharmaceuticals Ireland Limited

    Hyperlipidemia; Mixed

    phase 2 small molecule active

    1 trial

  44. ARO-DM1 Intravenous (IV) Infusion

    Arrowhead Pharmaceuticals Ireland Limited

    Myotonic Dystrophy 1

    phase 2 small molecule active

    1 trial

  45. ARO-DUX4 for Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Facio-Scapulo-Humeral Dystrophy

    phase 2 small molecule active

    1 trial

  46. ARO-ENaC

    Arrowhead Pharmaceuticals Ireland Limited

    Cystic Fibrosis, Pulmonary

    phase 2 small molecule terminated

    1 trial

  47. ARO-HBV

    Arrowhead Pharmaceuticals Ireland Limited

    Hepatitis B

    phase 2 small molecule completed

    1 trial

  48. ARO-HSD Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Non-alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.